SOLICITATION NOTICE
65 -- Boston Biosciences Protein EBov and CARS-CoV2 synthesis
- Notice Date
- 8/5/2020 10:23:58 AM
- Notice Type
- Presolicitation
- NAICS
- 325413
— In-Vitro Diagnostic Substance Manufacturing
- Contracting Office
- NATIONAL INSTITUTES OF HEALTH NIAID BETHESDA MD 20892 USA
- ZIP Code
- 20892
- Solicitation Number
- NOI-NIAID-2032622
- Response Due
- 8/14/2020 7:00:00 AM
- Archive Date
- 08/29/2020
- Point of Contact
- Skye Duffner, Phone: 4068026092, Julienne Keiser, Phone: 4063639370
- E-Mail Address
-
skye.duffner@nih.gov, jkeiser@niaid.nih.gov
(skye.duffner@nih.gov, jkeiser@niaid.nih.gov)
- Description
- This is a Notice of Intent, not a request for proposal. The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on an other than full and open competition basis with Boston Bioscience, Inc Royal Oak, MI 48073 for EBOV protein, 15 aa in length, C-terminal acid form, Free N-terminal form, EBOV protein, 15 aa in length, C-terminal acid form, Biotin-Ahx N-terminal form, SARS-CoV2 spike protein, 15 aa in length, C-terminal acid form, Free N-terminal form, and SARS-CoV2 spike protein, 15 aa in length, C-terminal acid form, Biotin-Ahx N-terminal form for assay development and immune analysis of vaccine recipient samples. The Vaccine Research Center (VRC) is performing critical work in pandemic response to SARS-CoV-2 infection (i.e., COVID-19). These efforts include analyzing SARS-CoV-2 specific immune responses following infection and vaccine induced immune response. This work is needed critically and urgently to support the pandemic response efforts of the VRC to SARS-CoV-2. This project seeks to apply a variety of different assay techniques to identify antigen-specific epitopes in serum following infection by or immunization against viral pathogens, using hundreds of customized peptides. Development of these assays will directly support pre-clinical assessment of novel coronavirus vaccines and support the effort in characterizing the Moderna coronavirus vaccine candidate. Boston Biosciences protocols are approved and in place to optimally synthesize and purify the difficult peptides. In addition, following their industry standard cleanup of impurities, Boston Biosciences has the additional proprietary cleanup of the peptides that is required and approved for our clinical trials. No substitutions are allowed on this project. The statutory authority for this sole source requirement is 41 U.S.C.1901 (e) (2) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide comparable services may submit a capability statement that will be considered by email (subject line to reference NOI-NIAID-2032622) to Skye Duffner at skye.duffner@nih.gov, by 10:00 am eastern standard time, August 14, 2020. All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.
- Web Link
-
SAM.gov Permalink
(https://beta.sam.gov/opp/e997eaeb66554202b348e3fc183d50d9/view)
- Place of Performance
- Address: Bethesda, MD 20892, USA
- Zip Code: 20892
- Country: USA
- Zip Code: 20892
- Record
- SN05746754-F 20200807/200805230200 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |